Immunohistochemistry and Radiomic Features for Survival Prediction in Small Cell Lung Cancer

Eleni Gkika, Matthias Benndorf, Benedict Oerther, Farid Mohammad, S. Beitinger, Sonja Adebahr, M. Carles, Tanja Schimek‐Jasch, Constantinos Zamboglou, Björn C. Frye, Fabian Bamberg, Cornelius F. Waller, Martin Werner, Anca-Ligia Grosu, Ursula Nestle, Gian KayserFrontiers in Oncology 2020 · DOI

TL;DR

This study investigated the predictive power of immunohistochemical (IHC) markers and radiomic features from CT scans for survival in Small Cell Lung Cancer (SCLC). While synaptophysin expression was linked to better overall survival and TTF-1/GLUT-1 to better progression-free survival, radiomic features showed only moderate correlations and did not independently predict survival.

What Problem Does This Paper Address?

Small Cell Lung Cancer (SCLC) is an aggressive cancer with a poor prognosis, characterized by rapid growth and early metastasis. Identifying reliable biomarkers for predicting treatment response and patient survival is crucial for personalized treatment strategies. While immunohistochemistry (IHC) is a standard diagnostic tool, its prognostic value in SCLC is not fully understood. Radiomics, which extracts quantitative features from medical images, offers a potential complementary approach to capture tumor heterogeneity and phenotype. However, the utility of radiomics in SCLC, particularly in conjunction with IHC, for survival prediction remains largely unexplored. This paper aims to bridge this gap by evaluating both IHC markers and radiomic features for their prognostic significance in SCLC patients.

Methods

The researchers conducted a retrospective analysis of 101 SCLC patients treated with radiotherapy and chemotherapy. They assessed the expression of several IHC markers from tumor biopsies, including neuroendocrine markers (CD56, chromogranin A, synaptophysin), proliferation markers (MIB-1/KI-67), and markers related to tumor microenvironment and metabolism (TTF-1, GLUT-1, HIF-1a, PD-1, PD-L1). For CD44, HIF-1a, and GLUT-1, semi-quantitative H-scores were calculated.

Additionally, a subgroup of 31 patients with homogenous CT scans underwent radiomic analysis. Seventy-two texture features were extracted from CT images using the PyRadiomics package. The study then correlated these IHC markers and radiomic features with overall survival (OS) and progression-free survival (PFS) using Kaplan-Meier analysis and Cox proportional hazards regression models.

Datasets

The study utilized data from 101 consecutive patients with histologically proven SCLC treated at the authors' institution. A subset of 31 patients from this cohort was used for the radiomics analysis, ensuring homogenous CT scan acquisition parameters. No new benchmark datasets were introduced.

Key Insights and Ideas

  • Synaptophysin as a Prognostic Indicator: The study highlights synaptophysin, a well-known neuroendocrine marker, as a significant predictor of better overall survival in SCLC. This suggests that its presence might indicate a less aggressive tumor phenotype or a better response to treatment.
  • TTF-1 and GLUT-1 in Progression-Free Survival: TTF-1 expression and a lower GLUT-1 H-score were associated with improved progression-free survival, indicating their potential role in predicting how long patients remain disease-free after treatment.
  • Radiomics' Limited Predictive Power in SCLC: Despite extracting a comprehensive set of radiomic features, the study found no single texture feature that strongly correlated with OS or PFS in SCLC. This suggests that, in this specific context and with the current radiomic feature set, imaging alone may not be sufficient for robust survival prediction.
  • Chromogranin A and PD-1 in Metastasis Risk: The absence of chromogranin A expression was linked to a higher risk of developing cerebral metastases, and PD-1 expression was associated with an increased risk of developing metastases in general. This points to potential roles for these markers in predicting metastatic spread.

Key Results

  • Overall Survival (OS): The median OS was 21 months for limited-stage SCLC and 13 months for extensive-stage SCLC. Synaptophysin expression correlated with a better OS (HR 0.546, p=0.03).
  • Progression-Free Survival (PFS): TTF-1 expression (HR 0.286, p=0.006) and a lower GLUT-1 H-score (HR 0.511, p=0.05) correlated with a better PFS.
  • Metastasis Risk: Patients without chromogranin A expression had a higher risk of cerebral metastases (p=0.02), and PD-1 expression was associated with an increased risk of developing metastases (p=0.02).
  • Radiomics: Correlation coefficients for radiomic features with OS ranged from -0.48 to 0.39, and for PFS from -0.46 to 0.38, indicating only moderate associations. No single radiomic feature independently predicted survival.

Limitations and Future Work

The authors acknowledge several limitations, including the retrospective nature of the study, its single-institution setting, a relatively small sample size, and potential selection bias in treatment delivery. They suggest that synaptophysin-negative patients might benefit from treatment intensification, warranting further evaluation. The limited predictive power of radiomics in this study suggests that future research could explore more advanced radiomic approaches, potentially integrating them with other data modalities like genomics or proteomics, or investigating different CT acquisition protocols. Further validation of the prognostic roles of TTF-1, GLUT-1, chromogranin A, and PD-1 in larger, prospective cohorts is also recommended.

Summary updated

Abstract

<b>Background:</b> The aim of the study was to evaluate the role of different immunohistochemical and radiomics features in patients with small cell lung cancer (SCLC). <b>Methods:</b> Consecutive patients with histologically proven SCLC with limited (<i>n</i> = 47, 48%) or extensive disease (<i>n</i> = 51, 52%) treated with radiotherapy and chemotherapy at our department were included in the analysis. The expression of different immunohistochemical markers from the initial tissue biopsy, such as CD56, CD44, chromogranin A, synaptophysin, TTF-1, GLUT-1, Hif-1 a, PD-1, and PD-L1, and MIB-1/KI-67 as well as LDH und NSE from the initial blood sample were evaluated. H-scores were additionally generated for CD44, Hif-1a, and GLUT-1. A total of 72 computer tomography (CT) radiomics texture features from a homogenous subgroup (<i>n</i> = 31) of patients were correlated with the immunohistochemistry, the survival (OS), and the progression-free survival (PFS). <b>Results:</b> The median OS, calculated from diagnosis, was 21 months for patients with limited disease and 13 months for patients with extensive disease. The expression of synaptophysin correlated with a better OS (HR 0.546 95% CI 0.308-0.966, <i>p</i> = 0.03). The expression of TTF-1 (HR 0.286, 95% CI: 0.117-0.698, <i>p</i> = 0.006) and a lower GLUT-1 H-score (median = 50, HR: 0.511, 95% CI: 0.260-1.003, <i>p</i> = 0.05) correlated with a better PFS. Patients without chromogranin A expression had a higher risk for developing cerebral metastases (<i>p</i> = 0.02) and patients with PD 1 expression were at risk for developing metastases (<i>p</i> = 0.02). Our radiomics analysis did not reveal a single texture feature that correlated highly with OS or PFS. Correlation coefficients ranged between -0.48 and 0.39 for OS and between -0.46 and 0.38 for PFS. <b>Conclusions:</b> The role of synaptophysin should be further evaluated as synaptophysin-negative patients might profit from treatment intensification. We report an, at most, moderate correlation of radiomics features with overall and progression free survival and no correlation with the expression of different immunohistochemical markers.
BibTeX
@inproceedings{gkika2020immunohistochemistry,
  author = {Eleni Gkika and Matthias Benndorf and Benedict Oerther and Farid Mohammad and S. Beitinger and Sonja Adebahr and M. Carles and Tanja Schimek‐Jasch and Constantinos Zamboglou and Björn C. Frye and Fabian Bamberg and Cornelius F. Waller and Martin Werner and Anca-Ligia Grosu and Ursula Nestle and Gian Kayser},
  title = {{Immunohistochemistry and Radiomic Features for Survival Prediction in Small Cell Lung Cancer}},
  booktitle = {Frontiers in Oncology},
  year = {2020},
  doi = {10.3389/fonc.2020.01161},
}
Figure